Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T ...
On September 6, Glenn received donor stem cells from a 23-year-old man located through the National Marrow Donor Program.
An announcement from Sanofi ( ($SNY) ) is now available. In October 2025, Sanofi faced a setback when the European Medicines Agency’s Committee ...
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for ...
Even for a newly minted Nobel laureate, downtime is hard to find. | Even for a newly minted Nobel laureate, downtime is hard ...
Designation places Mount Sinai among top one percent of cancer centers nationwide Mount Sinai Tisch Cancer Hospital Mount ...
Sanofi gained Rezurock in a $1.9 billion buyout of Kadmon in 2021, less than two months after the FDA approved the treatment ...
A recent clinical trial found that transplantation in lower-risk myelodysplastic syndrome (MDS) patients with high-risk ...
New research found that gene therapy for children with "bubble boy disease," or SCID, was successful in 95% of trial ...
Picture this: you’re surviving cancer, chemotherapy, radiation, immunosuppression, and a blood stem cell transplant, and you haven’t left the hospital in weeks. Yet, somehow, you have what feels and ...
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback